Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers
Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, US – MAINZ, Germany – JANUARY 5, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a […]
Mainz BioMed Appoints Karen Richards as Vice President, Regulatory Affairs to Lead US FDA Approval Process
BERKELEY, US – MAINZ, Germany – DECEMBER 21st, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Karen Richards as its Vice President of Regulatory Affairs. “It is a pleasure to welcome Karen to the management […]
Mainz Biomed Expands ColoAlert Commercialization with GANZIMMUN Diagnostics in Europe
Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in Germany GANZIMMUN Diagnostics has an interdisciplinary team of over 370 medical technical assistants, physicians, chemists, biologists, and nutritionists who process approximately 5,500 laboratory orders daily BERKELEY, US – MAINZ, Germany – DECEMBER 14th, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz […]
Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic
At-home Colorectal Cancer Diagnostic Test Now Available Online in Germany BERKELEY, US – MAINZ, Germany – DECEMBER 7th, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the launch of ColoAlert.de, an ecommerce store providing Germans direct […]
Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlert’s U.S. Regulatory and Commercial Strategy
BERKELEY, Calif. and MAINZ, Germany, Nov. 30, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announced today the Company has engaged Precision for Medicine, a leading global Clinical Research Organization, to provide U.S. regulatory and reimbursement advisory support for ColoAlert, […]
Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board
Former Danaher executive provides significant clinical, global market, and product development expertise in cancer diagnostics BERKELEY, CA – MAINZ, Germany – November 18, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Soren Thestrup-Nielsen M.D. […]
Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World’s Largest Medical Trade Fair
BERKELEY, US – MAINZ, Germany – NOVEMBER 15, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that Company representatives will be attending MEDICA 2021 to showcase ColoAlert, its highly efficacious and easy-to-use diagnostic test for colorectal […]
Mainz Biomed Appoints Former Roche Division President Heiner Dreismann to Strategic Advisory Board
Former President and CEO of Roche Molecular Systems and Member of Roche’s Global Diagnostic Executive Committee BERKELEY, Calif. and MAINZ, Germany, Nov. 11, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Heiner Dreismann to […]
Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ’
Flagship product ‘ColoAlert’ provides a unique, life-saving early detection test for colorectal cancer European registration completed and commercial rollout underway across multiple territories FDA clinical study process to be launched for U.S. regulatory approval BERKELEY, US – MAINZ, Germany – NOVEMBER 8, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular […]
MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market
BERKELEY, US – MAINZ, Germany – NOVEMBER 5, 2021 — Mainz Biomed N.V. (Nasdaq:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announces that its shares have commenced trading today on the Nasdaq Capital Market under the ticker symbol “MYNZ”. On November 4, 2021, the Company […]
